Jason J. Rose, MD, MBA

Dr. Rose completed a BSE in Biomedical Engineering from the University of Michigan in 2006 and went on to attend medical school at Wayne State University. He completed residency in Internal Medicine at Duke University Medical Center in 2013 before coming to the University of Pittsburgh in 2013 for his clinical and research fellowship training in Pulmonary, Allergy and Critical Care Medicine (PACCM). He joined the faculty of the University of Pittsburgh School of Medicine in 2016 and was recently promoted to Associate Professor of Medicine and Bioengineering. Dr. Rose obtained his MBA from the Tepper School of Business at Carnegie Mellon University in 2017 to pursue his entrepreneurial aspirations for drug development in the field of inhalational toxicology. He regularly rounds in medical intensive care unit with a clinical focus on mechanical ventilation, medical toxicology, and telemedicine in critical care.

His research work in carbon monoxide poisoning has contributed to the development of a novel class of antidotal therapies — leading to multiple patents and a spin-out company, Globin Solutions, Inc., which he co-founded in 2017. Dr. Rose currently serves as the President & CEO of Globin Solution. Under his leadership, Globin Solutions raised $5,500,000 in Series A funding in 2018 and was awarded a multi-PI Phase I/II Fast-Track STTR grant from the NIH in 2020. In support of his academic pursuits, he received a K08 award from the NIH, a Parker B Francis Fellowship, a Battlefield Resuscitation for Immediate Stabilization of Combat Casualties from the Department of Defense, a Young Investigator award from the American Heart Association, and a Young Physician-Scientist award from the American Society of Clinical Investigation.

Dr. Rose took on multiple leadership roles in developing innovation and commercialization opportunities for physician-scientists throughout while at the University of Pittsburgh School of Medicine. As Associate Vice Chair of Medicine, Dr. Rose partnered with UPMC Enterprises (the Investment Arm of UPMC health system) and the University of Pittsburgh to enhance innovative research and the commercialization of projects within the Department. He worked with Divisional leaders and Department faculty to connect investigators with the UPMC Enterprises Translational Sciences Portfolio and leverage their expertise and financial resources for commercialization of critical biomedical discoveries. During the COVID-19 pandemic, Dr. Rose served as Interim Director of Alternative Resourcing, assisting in Department efforts to explore innovative solutions to potential shortfalls in PPE and critical medical devices.

Dr. Rose is involved in multiple international academic medical organizations. He is active as a member of the Drug/Device Discovery and Development Committee of the American Thoracic Society (ATS) that fosters the bridge between leaders in respiratory therapeutics, academia, and the device industry. He also has served on multiple Early Career Committees in both the ATS and American Heart Association to enhance the development and professional opportunities of early-stage physician-scientists.

drug development carbon monoxide poisoning acute lung injury mechanical ventilation medical toxicology vaping e-cigarettes inhalational lung injury data science artificial intelligence (AI) machine learning robotics medical devices

Rose JJ, Bocian KA, Xu Q, Wang L, DeMartino AW, Chen X, Corey CG, Guimarães DA, Azarov I, Huang XN, Tong Q, Guo L, Nouraie M, McTiernan CF, O’Donnell CP, Tejero J, Shiva S, Gladwin MT. A neuroglobin-based high-affinity ligand trap reverses carbon monoxide-induced mitochondrial poisoning. J Biol Chem. 2020 May 8,295(19):6357-6310. doi: 10.1047/jbc.RA119.010593. PMID: 32205448. PMCID: PMC7212636

Triantafyllou GA, Tiberio PJ, Zou RH, Lynch MJ, Kreit JW, McVerry BJ, Morris A, Rose JJ. Long-term outcomes of EVALI: a 1-year retrospective study. Lancet Respir Med. 2021 Dec;9(12):e112-e113. doi: 10.1016/S2213-2600(21)00415-X. Epub 2021 Oct 25. PMID: 34710356; PMCID: PMC9074850.

Rose JJ, Nouraie M, Gauthier MC, Pizon AF, Saul MI, Donahoe MP, Gladwin MT. Clinical Outcomes and Mortality Impact of Hyperbaric Oxygen Therapy in Patients with Carbon Monoxide Poisoning. Crit Care Med. 2018 Jul;46(7):e649-e655. Apr 6. PMID: 29629990. PMCID: PMC6005724.

Azarov I*, Wang L*, Rose JJ*, Xu Q, Huang XN, Belanger A, Wang Y, Guo L, Liu C, Ucer KB, McTiernan CF, O'Donnell CP, Shiva S, Tejero J, Kim-Shapiro DB, Gladwin MT. Five-coordinate H64Q neuroglobin as a ligand-trap antidote for carbon monoxide poisoning. Sci Transl Med. 2016 Dec 7;8(368):368ra173. PMID: 27928027. PMCID: PMC5206801.

Rose JJ, Wang L, Xu Q, McTiernan CF, Shiva S, Tejero J, Gladwin MT. Carbon Monoxide Poisoning: Pathogenesis, Management, and Future Directions of Therapy. Am J Respir Crit Care Med. 2017 Mar 1;195(5):596-606. Review. PMID: 27753502. PMCID: PMC5363978.

DeMartino AW*, Rose JJ*, Amdahl MB, Dent MR, Shah FA, Bain W, McVerry BJ, Kitsios GD, Tejero J, Gladwin MT. No evidence of hemoglobin damage by SARS-CoV-2 infection. Haematologica. 2020 Sep 10; Online ahead of print (12):264267. doi: 10.3324/haematol.2020.264267. PMID: 33054129. PMCID: PMC7716349.

Zou RH, Tiberio PJ, Triantafyllou GA, Lamberty PE, Lynch MJ, Kreit JW, McVerry BJ, Gladwin MT, Morris A, Chiarchiaro J, Fitzpatrick ME, Rose JJ. Clinical Characterization of E-cigarette, or Vaping, Product Use Associated Lung Injury in 36 Patients in Pittsburgh, PA. Am J Respir Crit Care Med. 2020 May 15;201(10):1303-1306. Feb 5. doi: 10.1164/rccm.202001-0079LE. PMID: 32023422. PMCID: PMC7233355

Rose JJ, Newby LK, Broderick S, Chiswell K, Van de Werf F, Armstrong PW, Mahaffey KW, Harrington RA, Ohman EM, Giugliano RP, Goodman SG, White HD, Califf RM, Granger CB, Lopes RD. Left bundle branch block in non-ST-segment elevation acute coronary syndromes: Incidence, angiographic characteristics, and clinical outcomes.” J Am Coll Cardiol. 2013 Apr 2; 61(13):1461-3. PMID: 23500249.